Grail and National Health Service (NHS) England Complete Enrollment of 140,000 Participants in Largest Study of Multi-Cancer Early Detection Test
NHS-Galleri Trial is Evaluating Clinical Utility of GRAIL’s Galleri®, a Multi-Cancer Early Detection Test, Alongside Current Standard of Care in England NHS-Galleri Trial Prioritized Equitable Recruitment Approaches Designed to Achieve Representation of People from Minority Ethnic Backgrounds MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can … [Read more…]